DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY

Elizabeth Laws  1     Urvi Mujumdar  2     Bolanle Akinlade  3     Siddhesh Kamat  3     Paul J. Rowe  1     Leda Mannent  4     Juby A. Jacob-Nara  1     Albert J. Bredenoord  5     Marc E. Rothenberg     Jonathan Spergel     Evan S. Dellon     Qiong Zhao     Nikhil Amin     Yamo Deniz     Kiran Patel     Veronica Mas Casullo    
1 Sanofi,Bridgewater,United States
2 Sanofi,Cambridge,United States
3 Regeneron Pharmaceuticals, Inc,Tarrytown,United States
4 Sanofi,Chilly-Mazarin,France
5 Amsterdam University Medical Center,Amsterdam,Netherlands;

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing